George Mason University researchers led by Lance Liotta and Emanuel Petricoin have used laser capture microdissection combined with reverse phase protein microarray technology to help them identify three proteins interconnected within a single pathway that may determine whether conventional chemotherapy will be efficacious against a childhood form of cancer called rhabdomyosarcoma.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.